Robert R. Goodwin

Takeda Vaccines (Montana), Inc. operates as a biopharmaceutical company which focuses on the development of vaccines that prevent human infectious diseases. It specializes in developing vaccines against norovirus, influenza, and respiratory syncytial virus. The firm develops norovirus VLP vaccines that mimic the surface configuration of the live virus without the ability to cause infection, respiratory syncytial virus vaccine that mediates cell entry in its native form for use in anthrax treatment. The company was founded by Robert F. Bargatze on March 13, 2008 and is headquartered in Bozeman, MT.

Takeda Vaccines (Montana), Inc. operates as a biopharmaceutical company which focuses on the development of vaccines that prevent human infectious diseases. It specializes in developing vaccines against norovirus, influenza, and respiratory syncytial virus. The firm develops norovirus VLP vaccines that mimic the surface configuration of the live virus without the ability to cause infection, respiratory syncytial virus vaccine that mediates cell entry in its native form for use in anthrax treatment. The company was founded by Robert F. Bargatze on March 13, 2008 and is headquartered in Bozeman, MT.

Takeda Vaccines (Montana), Inc. operates as a biopharmaceutical company which focuses on the development of vaccines that prevent human infectious diseases. It specializes in developing vaccines against norovirus, influenza, and respiratory syncytial virus. The firm develops norovirus VLP vaccines that mimic the surface configuration of the live virus without the ability to cause infection, respiratory syncytial virus vaccine that mediates cell entry in its native form for use in anthrax treatment. The company was founded by Robert F. Bargatze on March 13, 2008 and is headquartered in Bozeman, MT.